EpiCast Report: Endometriosis - Epidemiology Forecast to 2022

Summary

Endometriosis is an estrogen-dependent disorder characterized by growth and appearance of endometrial cells or tissues in locations outside the uterus, which results in a series of chronic inflammatory reactions leading to scarring of tissues and adhesions of fibrous tissues in the pelvic region. Globally, the disease affects up to 10% of women. The condition is often associated with severe dysmenorrhea, chronic pelvic pain, chronic fatigue, deep dyspareunia, ovulation pain, abnormal bleeding and infertility.

The report provides an overview of the risk factors and global and historical trends for endometriosis in the 6MM. In addition, the report also includes a 10-year epidemiological forecast of the diagnosed prevalent cases of endometriosis segmented by age (in 5-year increments for women ages 15–49 years) and stages. GlobalData epidemiologists forecast that the diagnosed prevalent cases of endometriosis in the 6MM will grow from 5.66 million cases in 2012 to 5.86 million cases in 2022, at a growth rate of 3.4% over the forecast period.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of endometriosis in the 6MM, from 5.66 million prevalent cases in 2012 to 5.86 million prevalent case in 2022, at a growth rate of 3.4% over the forecast period. The US constituted the largest proportion (almost 90%) of the prevalent cases of endometriosis, with 5.24 million prevalent cases in 2022. Endometriosis is not a life-threatening condition and is largely influenced by hereditary factors. However, the condition will cause substantial economic, physical and psycho-social burden to the individual, as well as to the healthcare system, during the forecast period.

Scope

- The Endometriosis EpiCast Report provides an overview of the risk factors and global trends of endometriosis in the 6MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of the diagnosed prevalent cases of endometriosis segmented by age (in 5-year increments for women ages 15–49 years) and stages.

- The endometriosis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global endometriosis market.

- Quantify patient populations in the global endometriosis market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for endometriosis therapeutics in each of the markets covered.

Table Of Contents

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
3 Epidemiology 7
3.1 Disease Background 7
3.2 Risk Factors and Comorbidities 9
3.2.1 Family history is a strong predictor for the risk of endometriosis 10
3.2.2 Late age at menarche protects women from developing endometriosis 11
3.2.3 Higher parity decreases the risk for endometriosis 12
3.3 Global Trends 13
3.3.1 US 14
3.3.2 5EU 15
3.4 Forecast Methodology 16
3.4.1 Sources Used 17
3.4.2 Sources Not Used 19
3.4.3 Forecast Assumptions and Methods 20
3.5 Epidemiological Forecast of Endometriosis (2012-2022) 22
3.5.1 Diagnosed Prevalent Cases of Endometriosis 22
3.5.2 Age-Specific Prevalent Cases of Endometriosis 23
3.5.3 Age-Standardized Prevalence of Endometriosis 25
3.5.4 Diagnosed Prevalent Cases of Endometriosis by Stage 26
3.6 Discussion 27
3.6.1 Epidemiological Forecast Insight 27
3.6.2 Limitations of the Analysis 28
3.6.3 Strengths of the Analysis 30
4 Appendix 31
4.1 Bibliography 31
4.2 About the Authors 34
4.2.1 Epidemiologists 34
4.2.2 Reviewers 34
4.2.3 Global Director of Epidemiology and Health Policy 36
4.2.4 Global Head of Healthcare 36
4.3 About GlobalData 37
4.4 About EpiCast 37
4.5 Disclaimer 37



List of Tables

Table 1: Stages of Endometriosis (as per American Society of Reproductive Medicine) 8
Table 2: Risk Factors for Endometriosis 9
Table 3: Epidemiological Sources for Diagnosed Prevalence and Stages of Endometriosis 16
Table 4: 6MM, Diagnosed Prevalent Cases of Endometriosis, Ages 15-49 Years, N, 2012-2022 22
Table 5: 6MM, Prevalent Cases of Diagnosed Endometriosis, by Age, N, Row (%), 2012 24
Table 6: 6MM, Prevalent Cases of Diagnosed Endometriosis by Stages, Ages 15-49 Years, N, Row (%), 2012 26



List of Figures

Figure 1: 6MM, Diagnosed Prevalent Cases of Endometriosis, Ages 15-49 Years, N, 2012-2022 23
Figure 2: 6MM, Prevalent Cases of Diagnosed Endometriosis, by Age, N, 2012 24
Figure 3: 6MM, Age-Standardized Prevalence (%) of Diagnosed Endometriosis, Ages 15-49 Years, 2012 25
Figure 4: 6MM, Prevalent Cases of Diagnosed Endometriosis by Stage, Ages 15-49 Years, 2012 27

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022 Summary Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, ...

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most ...

Analytical Tool - Hematological Cancers

Analytical Tool - Hematological Cancers

  • $ 8 925
  • Industry report
  • March 2014
  • by Bioseeker

"Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.